Jesús Ruiz-Contreras

Jesús Ruiz-Contreras

Auto-generated profile, based on publicly available information

Jesús Ruiz-Contreras

Department of Pediatrics, Hospital Universitario 12 de Octubre, Madrid, Spain

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2006 in Blood
Verified
Journal Article
Closed access
PDF file
MDManuel Del-Rey
Manuel Del-Rey
JRJesus Ruiz-Contreras
Jesus Ruiz-Contreras
ABAlberto Bosque
Alberto Bosque
SCSara Calleja
Sara Calleja
JGJose Gomez-Rial
Jose Gomez-Rial
LALuis M. Allende
Luis M. Allende
Autoimmune lymphoproliferative syndrome (ALPS) is characterized by lymphoproliferation and autoimmune clinical manifestations and is generally caused by defective Fas-mediated apoptosis. This report describes the first homozygous FASL gene mutation in a woman with clinical and immunologic features of ALPS. T-cell blasts from the patient did not induce FasL-mediated apoptosis on Fas-transfected murine L1210 or on Jurkat cells, and activation-induced cell death was impaired. Furthermore, Fas-dependent cytotoxicity was drastically reduced in COS cells transfected with the mutant FasL. In addition, FasL expression on T-cell blasts from the patient was similar to that observed in a healthy control, despite its bearing the high-producer genotype –844C/C in the FASL promoter. Sequencing of the patient9s FASL gene revealed a new mutation in exon 4 (A247E). The location of A247E in the FasL extracellular domain and the conservation of the protein sequence of that region recorded in 8 species different from humans support the essential role of FasL COOH terminal domain in Fas/FasL binding. These findings provide evidence that inherited nonlethal FASL abnormalities cause an uncommon apoptosis defect producing lymphoproliferative disease, and they highlight the need for a review of the current ALPS classification to include a new ALPS type Ic subgroup.

22 September 2008 in Clinical and Experimental Immunology
Verified
Journal Article
Open access
PDF file
EMEsther Mancebo
Esther Mancebo
JCJ. Clemente
J. Clemente
JSJ. Sanchez
J. Sanchez
JRJ. Ruiz-Contreras
J. Ruiz-Contreras
PPP. De Pablos
P. De Pablos
LAL. M. Allende
L. M. Allende
The purpose of this study is to evaluate the effects of neonatal thymectomy in the functional capacity of the immune system. We selected a group of 23 subjects, who had undergone thymectomy in their first 30 days of life, during an intervention for congenital heart disease. Several parameters of the immune system were evaluated during their first 3 years of life. Lymphocyte populations and subpopulations (including naive, memory and effector subpopulations), T cell receptor (TCR) Vβ repertoire, response of T cells following in vitro stimulation by mitogen, quantification of immunoglobulins, TCR excision circles (TRECS) and interleukin (IL)-7 were measured. We found that neonatal thymectomy produces long-term diminution in total lymphocyte counts, especially in naive CD4+ and CD8+ T cells. Additionally, TRECS were decreased, and plasma IL-7 levels increased. A statistically significant negative correlation was found between absolute CD4+ T cells and IL-7 (r = −0·470, P = 0·02). The patients did not suffer more infectious events than healthy control children, but thymectomy in neonates resulted in a significant decrease in T lymphocyte levels and TRECS, consistent with cessation of thymopoiesis. This could produce a compromise in immune function later in life, especially if the patients suffer T cell depletion and need a reconstitution of immune function.

1 October 2003 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
JSJosé Manuel Sánchez
José Manuel Sánchez
JAJosé Tomás Ramos Amador
José Tomás Ramos Amador
SMSira Fernández De Miguel
Sira Fernández De Miguel
MTMaría Isabel González Tomée
María Isabel González Tomée
PCPablo Rojo Conejo
Pablo Rojo Conejo
AEAngel Nogales Espert
Angel Nogales Espert
Highly active antiretroviral therapy (HAART) slows the progression of HIV disease and lowers mortality and morbidity in adults. The impact on the disease course in children has not been still completely elucidated. Furthermore the effect of HAART on organ-specific complications of HIV is unknown. To assess the effect of HAART on the progression of HIV infection, mortality, organ-specific complications, number of infections and hospitalizations in HIV-1-infected children. Records of HIV-1-infected children were reviewed in a large referral pediatric hospital. Patients were divided into three groups: children who did not receive antiretroviral therapy (Group 1); children who received mono- or bitherapy (Group 2); and patients who received HAART (Group 3). Endpoints analyzed were progression to AIDS and mortality among AIDS patients and overall. One hundred seven children have been evaluated. Actuarial survival at 5 years of age was 33% in Groups 1 and 2 compared with 100% in Group 3 (P < 0.01). At 5 years of age, the proportion of children progressing to AIDS was 76% in Groups 1 and 2, compared with 26% in Group 3 (P < 0.01). At 5 years of follow-up, there were 45 cases of organ-specific complications in patients without HAART. No children without organ-specific complications when HAART was started have developed them after 5 years (P < 0.01). In patients without HAART there were 9 cases of lymphoid interstitial pneumonia, and there was none in Group 3 (P < 0.01). The incidence rates of infections and hospitalizations were 2.83 and 0.52 per patient-year, respectively, in children who did not receive HAART and 0.75 and 0.17 when they were managed with HAART (relative risk, 0.26 and 0.32). HAART is associated with a marked decline in the progression to AIDS, improved survival in HIV-1-infected children, reduced incidence of infections and hospitalizations and decreased incidence of some organ-specific complications of HIV.

1 May 2011 in Enfermedades Infecciosas y Microbiología Clínica
Verified
Journal Article
Closed access
JAJosé María Aguado
José María Aguado
IRIsabel Ruíz-Camps
Isabel Ruíz-Camps
PMPatricia Munoz
Patricia Munoz
JMJosé Mensa
José Mensa
BABenito Almirante
Benito Almirante
MCManuel Cuenca-Estrella
Manuel Cuenca-Estrella

1 July 2006 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
JRJaime Cruz Rojo
Jaime Cruz Rojo
JRJesús Ruiz-Contreras
Jesús Ruiz-Contreras
MFMaría Baro Fernández
María Baro Fernández
MMMiguel A. Marín
Miguel A. Marín
LFLola Folgueira
Lola Folgueira
Background: To determine the rates of influenza-related hospitalization and to know the clinical manifestations and underlying diseases in children younger than 3 years who are hospitalized with influenza. Methods: Retrospective, descriptive study (1996–2003), performed in a tertiary teaching hospital in Madrid. Data of hospitalized children, younger than 3 years, with influenza virus isolation from nasal aspirates were collected. Rates of hospitalization for every year were calculated. Results: Overall, 146 children hospitalized with influenza were identified: 117 had community-acquired influenza as the only disease, 18 had community-acquired influenza and were coinfected with other pathogens, and 11 had nosocomial infection. Rates of influenza hospitalization for years 1996, 1997, 1998, 1999, 2000, 2001, 2002, and 2003 were 0.42, 0.11, 1.46, 1.54, 0.53, 0.25, 0.19, and 0.82, respectively, per 1000 children younger than 3 years of age. Children ≤1 year of age accounted for almost two thirds of admissions. Bronchitis/bronchiolitis (42 children), pneumonia (11 children), fever without source (36 children), and suspected sepsis (9 children) accounted for almost 90% of all hospitalizations in children with community-acquired influenza. Forty-seven patients (40%) had underlying diseases, mainly chronic pulmonary disease and congenital heart disease. Ten patients (8.5%) with community-acquired influenza A and underlying conditions were admitted to the intensive care unit. Conclusions: Influenza is an important cause of hospitalization in young children. The use of influenza vaccine in high-risk children could prevent hospitalizations and cases of influenza-related diseases.

1 June 2013 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
JPJuan Picazo
Juan Picazo
JRJesus Ruiz-Contreras
Jesus Ruiz-Contreras
JCJuan Casado-Flores
Juan Casado-Flores
EGElisa Giangaspro
Elisa Giangaspro
MGMaria-Jesus García-De-Miguel
Maria-Jesus García-De-Miguel
CMCristina Méndez
Cristina Méndez
Background: Differences in invasive pneumococcal disease (IPD) in children are expected after a change from 7-valent pneumococcal conjugate vaccine (PCV7) to 13-valent pneumococcal conjugate vaccine (PCV13). Universal vaccination with PCV7 started in Madrid in November 2006, and it switched to PCV13 in June 2010. Methods: A prospective, laboratory-confirmed (by culture or polymerase chain reaction), clinical surveillance including all pediatric IPD requiring hospitalization in Madrid was performed in all hospitals with a pediatric department and included four 1-year periods from May 2007 to April 2011. Incidence rate (IR) was calculated as number cases per 100,000 inhabitants using children population data. Results: Six hundred fourteen IPDs were identified: 209 parapneumonic pneumococcal empyema, 191 bacteremic pneumonia, 75 primary bacteremia, 72 meningitis, 38 IPDs secondary to otic foci and 29 others. The incidence of IPD remained unchanged during 2007-2010 (IR=≈17.0), with a marked decrease in 2010-2011 (IR=11.34; P<0.05) attributable to reduction in children younger than 24 months (50.19 in 2008-2009 compared with 24.92 in 2010-2011; P<0.005). The incidence of bacteremic pneumonia (R2=0.966; β=1.132; P=0.017) and meningitis (R2=0.898; β=0.505; P=0.052) showed decreasing linear trends over time. The incidence of parapneumonic pneumococcal empyema increased in 2009-2010 but decreased in 2010-2011 (6.73 vs. 4.14; P=0.019). The incidence of IPDs by PCV13 serotypes was significantly (P≤0.004) lower in 2010-2011 (8.78) than in previous periods (IR=≈13.5). Conclusions: Early data regarding changing from PCV7 to PCV13 use in the childhood vaccination calendar indicate that reductions in IR of bacteremic pneumonia and meningitis after PCV7 introduction (by reduction of cases by serotypes 1 and 19A) further decreased and there was a reversion of the increase in IR of parapneumonic pneumococcal empyema from 2010-2011, mainly because of reduction in serotype 1 and 19A cases.